Ocular manifestations and viral shedding in tears of pediatric patients with coronavirus disease 2019: a preliminary report

Paola Valente, MD, PhD, Giancarlo Iarossi, MD, Matteo Federici, MD, Sergio Petroni, MD, Paolo Palma, MD, Nicola Cotugno, MD, Maria A. De Ioris, MD, PhD, Andrea Campana, MD, Luca Buzzonetti, MD

PII: S1091-8531(20)30115-4
DOI: https://doi.org/10.1016/j.jaapos.2020.05.002
Reference: YMPA 3192

To appear in: Journal of AAPOS

Received Date: 17 May 2020
Revised Date: 30 May 2020
Accepted Date: 30 May 2020

Please cite this article as: Valente P, Iarossi G, Federici M, Petroni S, Palma P, Cotugno N, De Ioris MA, Campana A, Buzzonetti L, Ocular manifestations and viral shedding in tears of pediatric patients with coronavirus disease 2019: a preliminary report, Journal of AAPOS (2020), doi: https://doi.org/10.1016/j.jaapos.2020.05.002.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2020, American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.
Ocular manifestations and viral shedding in tears of pediatric patients with coronavirus disease 2019: a preliminary report

Paola Valente, MD, PhD,a∗ Giancarlo Iarossi, MD,a∗ Matteo Federici, MD,a Sergio Petroni, MD,a Paolo Palma, MD,b Nicola Cotugno, MD,b Maria A. De Ioris, MD, PhD,c Andrea Campana, MD,c and Luca Buzzonetti, MDa

Author affiliations: aOphthalmology Department, Bambino Gesù IRCCS Pediatric Hospital, Rome, Italy; bAcademic Department of Pediatrics (DPUO), Unit of Perinatal Infection and Congenital Infectious Diseases, Bambino Gesù IRCCS Pediatric Hospital, Rome, Italy; cPediatric Department, Bambino Gesù IRCCS Pediatric Hospital, Rome, Italy

∗These authors contributed equally to the paper.

Correspondence: Paola Valente, MD, Ophthalmology Department, Bambino Gesù IRCCS Pediatric Hospital, Via Torre di Palidoro snc – 00050 Passoscu (Rome), Italy (email: paola.valente@opbg.net).

Word count: 1,741
Abstract only: 218
Abstract

Purpose
To evaluate ocular manifestations and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) prevalence in the tears of children with coronavirus disease 2019 (COVID-19).

Methods
A total of 27 pediatric patients with confirmed COVID-19 infection hospitalized from March 16 to April 15, 2020, at the Bambino Gesù Children’s Hospital were enrolled in the study. At admission, all patients showed ocular manifestations. Reverse transcriptase–polymerase chain reaction from nasopharyngeal and conjunctival swabs were performed every 2-3 days before discharge.

Results
Of the 27 patients, 4 (15%) were asymptomatic, 15 (56%) showed respiratory symptoms, and 8 (30%) had gastrointestinal symptoms. At admission, nasopharyngeal swabs were positive for COVID-19 in all patients; on the second swabs, 7 children (26%) tested negative, and 20 remained positive for COVID-19. Ocular manifestations consistent with mild viral conjunctivitis were observed in 4 patients (15%). At first conjunctival swab, 3 patients (11%), 1 symptomatic and 2 asymptomatic for ocular infection, had positive findings for COVID-19; 2 became negative on the second test and 1 on the third.

Conclusions
In our study cohort, ocular manifestations of COVID-19 seem to have had a milder clinical course in pediatric patients than in adults. Despite the low prevalence and rapid regression of viral presence in the conjunctiva, SARS-CoV-2 transmission through tears may be possible, even in patients without apparent ocular involvement.
Since its onset in December 2019 in Wuhan (Hubei Province, China) the coronavirus disease 2019 (COVID-19) has quickly spread across the globe, causing a global pandemic, according to the World Health Organization (WHO). The pathogen of COVID-19 is a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can cause multiple system infections but mainly respiratory tract infections, such as severe acute respiratory syndrome. The most common signs and symptoms include fever, cough, fatigue, myalgia, dyspnea, diarrhea.

Compared with adults, children with COVID-19 seem to have lower incidence, shorter course of disease, and a more favorable clinical presentation and prognosis. The transmission route of this novel coronavirus (SARS-CoV-2) remains unclear, and most authors report that it occurs mainly through direct contact or respiratory droplets. Previous studies have investigated the viral presence in tears of patients with SARS-CoV-1 and SARS-CoV-2, reporting controversial results. All of these studies were performed in adult patients. In this study we evaluated ocular involvement and the SARS-CoV-2 virus shedding in tears of 27 pediatric patients admitted to the Bambino Gesù Children’s Hospital (BGCH) COVID Center in order to better understand the pathogenicity of SARS-CoV-2 in children’s eyes.

**Subjects and Methods**

This study was approved by the Bambino Gesù Children’s Hospital Ethics Committee and adhered to the tenets of the Declaration of Helsinki. Informed consent to the procedure was obtained for each patient. This prospective observational case series study included 27 pediatric patients (7 females; mean age, 84 months; age range, 8 days to 210 months) with infection confirmed by nasopharyngeal swab COVID-19 nucleic acid test.

All patients were hospitalized from March 16 to April 15, 2020, at BGCH in the COVID-
dedicated inpatient service created for the management of the SARS-COV-2 pandemic. Clinical data, including demographic information, contact history, clinical symptoms, and laboratory findings were reviewed and analyzed. Ocular symptoms and signs were also recorded. Real-time reverse transcriptase–polymerase chain reaction (RT-PCR) tests (GeneXpert, Cepheid, Sunnyvale, CA; 250 copies/mL sensitivity, 100% specificity) from nasopharyngeal and conjunctival swabs were performed on admission and repeated every 2-3 days before discharge; the microbiological surveillance was discontinued after two consecutive negative samples.

Swabs to collect tears and conjunctival secretions were performed from the lower eyelid fornix without topical anesthesia to avoid possible contamination of the specimen. Follow-up for each patient continued through April 15, 2020. The laboratory tests were performed in accordance with the guidelines and in laboratories identified for COVID-19 detection by the Italian Health Ministry.

**Results**

Clinical and demographic data of patients are summarized in Table 1. On admission, 23 patients were symptomatic: 15 patients (56%) showed respiratory symptoms (cough or dyspnea with or without fever), and 8 patients (30%) had gastrointestinal symptoms (vomiting and/or diarrhea with or without fever). No systemic symptoms were detected in 3 newborns whose mothers were infected. Average time from symptoms to admission was 7 days (range, 0-19).

On hospital admission, nasopharyngeal swab to COVID-19 tested positive in all patients. The swabs were repeated on average 4 times (range, 2-8) before discharge. Of the 27 children, 7 had negative findings for COVID-19 on second nasopharyngeal swab, and 20 had positive results.

Of the 27 patients, 4 (15%) had ocular manifestations consistent with viral conjunctivitis,
characterized by mild conjunctival hyperemia and secretion; of these, 1 patient resulted positive for SARS-CoV-2 on RT-PCR from conjunctival swab, whereas no signs of viral shedding were found in the other 3. Clinical resolution of conjunctivitis was achieved in all patients 3-5 days after onset. Two more patients had positive findings for SARS-CoV-2 in their conjunctival swab without developing clinical signs of conjunctivitis. Three patients (11%) had positive findings for COVID-19 on first conjunctival swab; of these, the 2 asymptomatic cases became negative at the second swab (3 days) and the symptomatic case at the third (6 days), while remaining positive on nasopharyngeal swabs.

Additionally, the nasopharyngeal swab was negative on average 8 days (range, 2-17 days) from onset of symptoms, whereas conjunctival swab became negative in all patients on average in 4 days (range, 3-6 days).

**Discussion**

The novel COVID-19 caused by SARS-CoV-2 emerged in December 2019 in Wuhan, China. Virologic data has demonstrated that individuals carry potentially infectious SARS-CoV-2 particles in their nasopharyngeal secretions, thereby very likely contributing to COVID-19 transmission; therefore, positive SARS-CoV-2 RNA swabs are indicative of active infection. The epidemiology and clinical course of SARS-CoV-2 seems to differ in childhood compared with adults, with a mean lower incidence and milder symptoms in the pediatric population.

Several reports have investigated ocular involvement in adult patients with COVID-19 infection. Wu and colleagues evaluated 38 adult patients with clinically confirmed COVID-19 reporting that one-third of patients with more severe systemic manifestations had conjunctivitis despite a low prevalence of positive findings for SARS-CoV-2 in their conjunctival swabs. Xia and colleagues confirmed this evidence as viral RNA in tear fluid, and
conjunctival secretion was found in the only patient affected by conjunctivitis of 30 adults with SARS-CoV-2 infection examined. Additionally, a viral replication has been recently reported in tear fluid of a COVID-19 patient with conjunctivitis after clinical resolution of symptoms and clearance of conjunctival and nasal swabs, indicating ocular mucosa as a site of sustained viral replication and consequently a source of contagion. Zhou and colleagues\(^{18}\) observed that in adults symptoms and findings, when present, were mild.

On the contrary, Seah and colleagues\(^{13}\) found that in 17 adult patients with ocular symptoms, including red eye, tearing, blurring of vision, discharge, and color desaturation, there was no evidence of SARS-CoV-2 shedding in tear fluid in all patients through the course of the disease, suggesting a low risk of infection transmission through tears.

The current evaluated a cohort of pediatric patients with COVID-19 infection. Ocular involvement consistent with conjunctivitis was found only in 3 of 27 children and appeared to have a mild clinical course that resolved in a few days. This finding accords with the more benign systemic manifestation of the disease reported for pediatric patients compared with adults. Only a single patient affected by conjunctivitis was positive by swab testing. This apparent discrepancy could be explained by the timing of the test, which may not have been coincidental with the viral maximal load, or by the limited quantity of tear and conjunctival secretions collected, determining an insufficient sample concentration for RT-PCR detection of the virus. However, as in with previous studies, our data showed only a small prevalence of positive swabs in patients with manifest signs of conjunctivitis.

Nevertheless, ocular viral shedding was found in 3 patients, suggesting, as other authors have reported for adult populations, that transmission through tears is possible in children. Furthermore, of the 3 patients with positive conjunctival swabs, only 1 child presented ocular
manifestations, indicating that viral load may be present in tears even in asymptomatic patients.

Another issue is the difference between nasopharyngeal and ocular viral shedding trends. In our patients, the conjunctival swab became negative in all patients much sooner than did the nasopharyngeal swab. In most of the cases, patients with persistent positive nasopharyngeal swab over days maintained a negative conjunctival swab, confirming that the viral load in the tear fluid is less than in other biological specimens and that the eye is relatively preserved in comparison with other organs. In consideration of these findings, conjunctival swab should not be considered a valuable diagnostic test of COVID-19, particularly in children. Nevertheless, despite the low prevalence and rapid regression of viral presence in the conjunctiva, transmission through tears is theoretically possible, even if the ocular contagious phase in children seems to be relatively brief. This contrasts with the evidence of long viral persistence and replication in conjunctiva recently reported in adults, but it might be explained by the milder manifestation of the disease in the pediatric population.

Of the children hospitalized for COVID-19, identification of SARS-COV-2 RNA from ocular secretions was uncommon. Of the 3 children (11%) found to have SARS-COV-2 RNA in tears, 2 were without ocular signs or symptoms and 1 had mild conjunctivitis. PCR-based shedding of SARS-CV-2 tended to clear faster from tears than from oropharyngeal secretions (median, 4 vs 8 days), although the ranges were wide, with sizable overlap (2-17 vs 3-6 days, resp.).

This study has some limitations, including its relatively small sample size. Another is the uncertainty of the efficacy of RT\textsuperscript{PC}R as a technique for diagnosing SARS-CoV-2 in tears.\textsuperscript{19,20} False-negative results, usually due to sample contamination or insufficient sample concentration for RT\textsuperscript{PC}R virus detection, could not be ruled out, mainly in children whose poor compliance
may hinder the collection of tears and conjunctival secretion. To decrease false negatives, we repeated the test at least twice for each patient before discharge.

In conclusion, our preliminary data confirms the relatively milder symptoms experienced by pediatric patients and supports the possible presence of viral load in tears and conjunctival secretion. Thus, although pediatric ocular manifestations in COVID-19 seem to be mild, there is still a risk of transmission. Although SARS-CoV-2 prevalence is low in tears and may disappear, potential ocular transmission must be considered by clinicians treating pediatric patients, in whom disease effects may be milder and eye involvement mostly asymptomatic but hand-to-face contact is common.
References

1. World Health Organization. Coronavirus disease 2019 (COVID-19). Situation Report – 84. Available from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200413-sitrep-84-covid-19.pdf?sfvrsn=44f511ab_2.

2. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565-74.

3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. Epub ahead of print, 2020 Feb 24. JAMA.

4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433.

5. Singhal T. A Review of coronavirus disease 2019 (COVID-19). Indian J Pediatr 2020;87:281-6.

6. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020;109:1088-95.

7. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr 2020;63:125-32.

8. Loon SC, Teoh SC, Oon LL, et al. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol 2004;88:861-3.

9. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? a review of coronaviruses and ocular implications in humans and animals. Ocul Immunol
Inflamm 2020;28:391-5.

10. Colavita F, Lapa D, Carletti F, et al. SARS-CoV-2 Isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection. Ann Intern Med 2020;M20-1176.

11. Lu CW, Liu XF, Jia ZF. 2019 nCoV transmission through the ocular surface must not be ignored. Lancet 2020;395:e39.

12. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol 2020 Feb 26. doi:10.1002/jmv.25725.

13. Seah IYJ, Anderson DE, Kang AEZ, et al. Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. Ophthalmology 2020;S0161-6420(20)30311-0.

14. Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020;138:575–8.

15. Hagmann SHF. COVID-19 in children: more than meets the eye. Travel Med Infect Dis 2020;34:101649.

16. Denison MR. Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: an update. Pediatr Infect Dis J 2004; 23:S207-14.

17. Al-Tawfiq JA, Kattan RF, Memish ZA. Middle East respiratory syndrome coronavirus disease is rare in children: an update from Saudi Arabia. World J Clin Pediatr 2016;5:391-6.

18. Zhou Y, Duan C, Zeng Y et al. Ocular findings and proportion with conjunctival SARS-
COV-2 in COVID-19 patients. Ophthalmology 2020;S0161-6420(20)30405-X.

19. Loon SC, Teoh SCB, Oon LLE, et al. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol 2004;88:861-3.

20. Lin C, Ye R, Xia YL. A meta-analysis to evaluate the effectiveness of real-time PCR for diagnosing novel coronavirus infections. Genet Mol Res 2015;14:15634-41.
Table 1. Patients characteristics

| Case | Age, mos | Days S–A | Systemic symptoms | Ocular manifestations | Pharyngeal swab | Conjunctival swab |
|------|----------|----------|-------------------|----------------------|----------------|------------------|
|      |          |          | Fever | Respiratory | Gastrointestinal | First | Second | First | Second |
| 1    | 52       | 12       | +     | –          | +              | Pos    | Pos    | Pos   | Neg    |
| 2    | 6        | 6        | +     | –          | +              | Pos    | Pos    | Pos   | Neg    |
| 3    | 8        | 14       | +     | +          | +              | Pos    | Pos    | Neg   | Neg    |
| 4    | 204      | 5        | +     | +          | –              | Pos    | Pos    | Neg   | Neg    |
| 5    | 12       | 8        | +     | +          | –              | Pos    | Pos    | Neg   | Neg    |
| 6    | 168      | 6        | +     | +          | –              | Pos    | Pos    | Neg   | Neg    |
| 7    | 210      | 6        | +     | +          | –              | Pos    | Pos    | Neg   | Neg    |
| 8    | 192      | 2        | +     | –          | –              | Pos    | Pos    | Neg   | Neg    |
| 9    | 216      | 7        | +     | +          | –              | Pos    | Neg    | Neg   | Neg    |
| 10   | 25       | 8        | +     | +          | +              | Pos    | Neg    | Neg   | Neg    |
| 11   | 133      | 9        | +     | +          | –              | Pos    | Pos    | Neg   | Neg    |
| 12   | 84       | 19       | –     | +          | –              | Pos    | Pos    | Neg   | Neg    |
| 13   | 1        | 5        | –     | –          | –              | Pos    | Pos    | Neg   | Neg    |
| 14   | 1        | 3        | –     | +          | +              | Pos    | Neg    | Neg   | Neg    |
| 15   | 1        | 6        | +     | +          | –              | Pos    | Neg    | Neg   | Neg    |
| 16   | 1        | 8        | –     | –          | –              | Pos    | Neg    | Neg   | Neg    |
| 17   | 180      | 1        | +     | +          | –              | Pos    | Pos    | Pos   | Pos    |
| 18   | 81       | 6        | +     | –          | +              | Pos    | Pos    | Neg   | Pos    |
| 19   | 137      | 11       | –     | –          | +              | Pos    | Pos    | Neg   | Neg    |
| 20   | 180      | 16       | –     | +          | –              | Pos    | Pos    | Neg   | Neg    |
| 21   | 81       | 1        | –     | –          | –              | Pos    | Pos    | Neg   | Neg    |
| 22   | 108      | 3        | –     | –          | –              | Pos    | Pos    | Neg   | Neg    |
| 23   | 76       | 0        | +     | –          | –              | Pos    | Pos    | Neg   | Neg    |
| 24   | 69       | 11       | –     | +          | –              | Pos    | Pos    | Neg   | Pos    |
| 25   | 34       | 5        | –     | +          | –              | Pos    | Pos    | Pos   | Pos    |
| 26   | 183      | 2        | +     | +          | –              | Pos    | Neg    | Neg   | Neg    |
| 27   | 156      | 9        | +     | –          | –              | Pos    | Neg    | Neg   | Neg    |

*aDays from onset of symptoms to admission.*